To the full analysis
Haemonetics stock: growth
HAEHaemonetics reported $1.33B in revenue for fiscal 2026, down 2% on the prior year, up 8.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.9%
per year from 2007 to 2026, per share 6.6%
Earnings (Annual rate)
3.7%
per year from 2007 to 2026, per share 4.3%
Free cash flow (Annual rate)
10.1%
per year from 2007 to 2026, per share 10.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 8.9% | 3.9% | 5.9% |
| Revenue per share | 10.5% | 4.7% | 6.6% |
| Earnings | 4.1% | no data | 3.7% |
| Earnings per share | 5.5% | no data | 4.3% |
| Free cash flow | 29.4% | 29.6% | 10.1% |
| Free cash flow per share | 31.3% | 30.6% | 10.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $449.61M | $49.11M | $42.11M |
| 2008 | $516.44M | $51.98M | $19.88M |
| 2009 | $597.88M | $59.3M | $59.99M |
| 2010 | $645.43M | $58.38M | $74.36M |
| 2011 | $676.69M | $79.98M | $76.79M |
| 2012 | $727.84M | $66.89M | $62.12M |
| 2013 | $891.99M | $38.8M | $22.89M |
| 2014 | $938.51M | $35.15M | $65.88M |
| 2015 | $910.37M | $16.9M | $4.96M |
| 2016 | $908.83M | −$55.62M | $19.46M |
| 2017 | $886.12M | −$26.27M | $83.6M |
| 2018 | $903.92M | $45.57M | $145.55M |
| 2019 | $967.58M | $55.02M | $40.32M |
| 2020 | $988.48M | $76.53M | $109.46M |
| 2021 | $870.46M | $79.47M | $71.77M |
| 2022 | $993.2M | $43.38M | $75.75M |
| 2023 | $1.17B | $115.4M | $162.87M |
| 2024 | $1.31B | $117.56M | $143.63M |
| 2025 | $1.36B | $167.68M | $142.45M |
| 2026 | $1.33B | $97.31M | $260.44M |
Revenue by region
Where Haemonetics Corporation generates its revenue.
- United States74%
- Europe14%
- Asia7%
- Japan5%
- Other< 1%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $522.69M | $548.73M | $606.85M | $646.2M | $522.61M | $639.32M | $842.9M | $970.01M | $1.01B | $982.18M | 73.6% |
| Europe | $166.01M | $164.23M | $164.5M | $153.35M | $159.08M | $163.52M | $156.68M | $160.14M | $175.66M | $185.02M | 13.9% |
| Asia | $109.86M | $115.13M | $118.7M | $109.3M | $105.82M | $110.8M | $104.14M | $107.54M | $92.31M | $87.21M | 6.5% |
| Japan | $79.27M | $67.32M | $69.91M | $72.22M | $77.68M | $75.56M | $61.3M | $58.09M | $62.41M | $68.2M | 5.1% |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $13.28M | $19.54M | $0 | 0% |
| Total revenue | $886.12M | $903.92M | $967.58M | $988.48M | $870.46M | $993.2M | $1.17B | $1.31B | $1.36B | $1.33B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 28 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.